Accordingly, pharmacological treatments aimed at increasing global acetylation levels through the use of non-selective pan-HDAC inhibitors have shown promising effects in reversing cognitive deficits in a variety of neurodegenerative animal models [99] making this a powerful therapeutic strategy [100–103]. This evidence concerns the gene HDAC9 and Cognitive impairment.